Mimpara® 30 mg film-coated tablets

(Cinacalcet)

UK6280514P99-A2.0

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only.
  Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

This product is called Mimpara 30 mg film-coated tablets but will be referred to as Mimpara throughout the leaflet.

What is in this leaflet

1. What Mimpara is and what it is used for

Mimpara works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorous in your body. It is used to treat problems with organs called parathyroid glands. The parathyroids are four small glands in the neck, near the thyroid gland, that produce parathyroid hormone (PTH).

Mimpara is used in adults:
- to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis to clear their blood of waste products.
- to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with parathyroid cancer.
- to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with primary hyperparathyroidism when removal of the gland is not possible.

Mimpara is used in children aged 3 years to less than 18 years of age:
- to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products, whose condition is not controlled with other treatments.

In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroid glands. “Primary” means that the hyperparathyroidism is not caused by any other condition and “secondary” means that the hyperparathyroidism is caused by another condition, e.g. kidney disease. Both primary and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.

2. What you need to know before you take Mimpara

Do not take Mimpara if you are allergic to cinacalcet or any of the other ingredients of this medicine (listed in section 6).

Do not take Mimpara if you have low levels of calcium in your blood. Your doctor will monitor your blood calcium levels.

Warnings and precautions
Talk to your doctor,
pharmacist or nurse before taking Mimpara.

Before you start taking Mimpara, tell your doctor if you have or have ever had:
- **seizures**
  (fits or convulsions).
  The risk of having seizures is higher if you have had them before;
- **liver problems;**
- **heart failure.**

Mimpara reduces calcium levels. Life threatening events and fatal outcomes associated with low calcium levels (hypocalcaemia) have been reported in adults and children treated with Mimpara.

Please tell your doctor if you experience any of the following which may be signs of low calcium levels: spasms, twitches, or cramps in your muscles, or numbness or tingling in your fingers, toes or around your mouth or seizures, confusion or loss of consciousness while being treated with Mimpara.

Low calcium levels can have an effect on your heart rhythm. Tell your doctor if you experience an unusually fast or pounding heartbeat, if you have heart rhythm problems,
or if you take medicines known to cause heart rhythm problems, while taking Mimpara.
For additional information see section 4.

During treatment with Mimpara, tell your doctor:
- if you start or stop smoking, as this may affect the way Mimpara works.

Children and adolescents
Children under the age of
18 with parathyroid cancer or primary hyperparathyroidism must not take Mimpara.

If you are being treated for secondary hyperparathyroidism, your doctor should monitor your calcium levels before starting treatment with Mimpara and during treatment with Mimpara. You should inform your doctor if you experience any of the signs of low calcium levels as described above.

It is important that you take your dose of Mimpara as advised by your doctor.

Other medicines and Mimpara
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines particularly etelcalcetide or any other medicines that lower the level of calcium in your blood.

You should not receive Mimpara together with etelcalcetide.

Tell your doctor if you are taking the following medicines

Medicines such as these can affect how Mimpara works:
- medicines used to treat **skin** and **fungal infections** (ketoconazole, itraconazole and voriconazole);
- medicines used to treat **bacterial infections** (telithromycin, rifampicin and ciprofloxacin);
- a medicine used to treat **HIV** infection and AIDS (ritonavir);
- a medicine used to treat **depression** (fluvoxamine).

Mimpara may affect how medicines such as the following work:
- medicines used to treat **depression** (amitriptyline, desipramine, nortriptyline and clomipramine);
- a medicine used to relieve **cough** (dextromethorphan);
- medicines used to treat **changes in heart rate** (flecainide and propafenone);
- a medicine used to treat **high blood pressure** (metoprolol).

Mimpara with food and drink
Mimpara should be taken with or shortly after food.

Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Mimpara has not been tested in pregnant women. In case of pregnancy, your doctor may decide to modify your treatment, as Mimpara might harm the unborn baby.

It is not known whether Mimpara is excreted in human milk. Your doctor will discuss with you if you should discontinue either breast-feeding or treatment with Mimpara.

Driving and using machines
Dizziness and seizures have been reported by patients taking Mimpara. If you experience these side effects, do not drive or operate machines.

Mimpara contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Mimpara

Always take this medicine exactly as your doctor or pharmacist has told you.
Check with your doctor or pharmacist if you are unsure. Your doctor will tell you how much Mimpara you must take.

Mimpara must be taken orally, with or shortly after food. The tablets must be taken whole and are not to be chewed, crushed or divided.
Mimpara is also available as granules in capsules for opening. Children who require doses lower than 30 mg, or who are unable to swallow tablets should receive Mimpara granules.

Your doctor will take regular blood samples during treatment to monitor your progress and will adjust your dose if necessary.

If you are being treated for secondary hyperparathyroidism
The usual starting dose for Mimpara in adults is 30 mg (one tablet) once per day.

The usual starting dose of Mimpara for children aged 3 years to less than 18 years of age is no more than 0.20 mg/kg of body weight daily.

If you are being treated for parathyroid cancer or primary hyperparathyroidism
The usual starting dose for Mimpara in adults is 30 mg (one tablet) twice per day.

If you take more Mimpara than you should
If you take more Mimpara than you should you must contact your doctor immediately. Possible signs of overdose include numbness or tingling around the mouth, muscle aches or cramps and seizures.

If you forget to take Mimpara
Do not take a double dose to make up for a forgotten dose.

If you have forgotten a dose of Mimpara, you should take your next dose as normal.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Please tell your doctor immediately:
- If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures. These may be signs that your calcium levels are too low (hypocalcaemia).
- If you experience swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema).

Very common: may affect more than 1 in 10 people
- nausea and vomiting, these side effects are normally quite mild and do not last for long.

Common: may affect up to 1 in 10 people
- dizziness
- numbness or tingling sensation (paraesthesia)
- loss (anorexia) or decrease of appetite
- muscle pain (myalgia)
- weakness (asthenia)
- rash
- reduced testosterone levels
- high potassium levels in the blood (hyperkalaemia)
- allergic reactions (hypersensitivity)
- headache
- seizures (convulsions or fits)
- low blood pressure (hypotension)
- upper respiratory infection
- breathing difficulties (dyspnoea)
- cough
- indigestion (dyspepsia)
- diarrhoea
- abdominal pain, abdominal pain – upper
- constipation
- muscle spasms
- back pain
- low calcium levels in the blood (hypocalcaemia).

Not known: frequency cannot be estimated from available data
- Hives (urticaria)
- Swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema)
- Unusually fast or pounding heart beat which may be associated with low levels of calcium in your blood (QT prolongation and ventricular arrhythmia secondary to hypocalcaemia).

After taking Mimpara a very small number of patients with heart failure had worsening of their condition and/or low blood pressure (hypotension).

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

You can also report side effects directly via the Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the **Google Play** or **Apple App Store**

5. How to store Mimpara

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

This medicinal product
does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

If the medicine becomes discolored or shows any other signs of deterioration, you should seek the advice of your pharmacist who will tell you what to do.

6. Contents of the pack and other information

What Mimpara contains
- The active substance is cinacalcet. Each film-coated tablet contains
  30 mg of cinacalcet
  (as hydrochloride).
- The other ingredients are:
  - Pre-gelatinised maize starch
  - Microcrystalline cellulose
  - Povidone
  - Crospovidone
  - Magnesium stearate
  - Colloidal anhydrous silica

- The tablets are coated with:
  - Carnauba wax
  - Opadry green (containing lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate, FD&C Blue (E132), iron oxide yellow (E172))
  - Opadry clear (containing hypromellose, macrogol)

What Mimpara looks like and contents of the pack
Mimpara is a light green
film-coated tablet. They are oval-shaped and have
“30” marked on one side and “AMG” on the other side.

30 mg tablets are approximately 9.7 mm long and 6.0 mm wide.

Mimpara is available in blisters of 30 mg film-coated tablets. Each blister pack contains 28 tablets in a carton.

Not all pack sizes may be marketed.

Manufacturer
Amgen Europe B.V.
Minervum 7061
4817 ZK Breda
The Netherlands

Procured from within the EU and repackaged for the PL Holder:
Abacus Medicine Ltd.,
Abbey House,
282 Farnborough Road, Farnborough, GU14 7NA, United Kingdom

Mimpara® is a registered trademark of Amgen Inc.

PL 45763/0514

This leaflet was last revised on 16/05/2025.

POM

For any information about this medicine, please contact the local representative of the Product Licence Holder: Abacus Medicine Ltd.
tel: +44(0)2036301244,
email: MedInfo@abacusmedicine.co.uk
or
drugsafetyuk@abacusmedicine.co.uk

Blind or partially sighted? Is this leaflet hard to see or read? Call 02036301310 or write to info@abacusmedicine.com to obtain the leaflet in a format suitable for you.